1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Standard Chemical & Pharmaceutical Co. Ltd.

Standard Chemical & Pharmaceutical Co. Ltd.

TTWSE:1720
57.00
TWD
+0.20
(+0.35%)
6.85EPS
11.28P/E
11.31BMarket Cap
Standard Chemical & Pharmaceutical Co. Ltd.
TWSE:1720
(Taiwan Stock Exchange)

Recent

price

57.00

P/E

ratio

11.28

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
15.75
17.99
18.21
16.12
16.77
16.9
18.69
19.58
18.18
20.03
21.9
23.42
29.77
31.74
34.54
35.73
35.16
Revenue per Share
1.14
1.33
1.49
1.58
1.9
1.77
1.73
1.85
1.9
1.92
2.67
3.6
4.15
4.25
4.48
4.72
5.1
Basic EPS, GAAP
-0.86
0.66
1.24
0.03
2.05
2.37
0.65
1.64
1.61
2.41
2.9
3.1
0.15
3.6
5.57
6.43
5.9
Free Cash Flow per Basic Share
1.36
0.42
0.91
1.08
2.27
0.91
1.36
1.36
1.45
1.36
1.36
1.64
2.27
2.27
2.45
2.55
- -
Dividend per Share
14.68
14.8
15.41
16.74
16.81
18.03
18.92
18.68
18.73
17.22
20.18
22.09
24.18
26.96
30.04
31.16
31.5
Book Value per Share
13.81
13.98
14.52
15.99
16.07
17.35
18.31
18.08
18.16
16.78
19.72
20.95
23.04
25.87
28.98
30.1
30.47
Tangible Book Value per Share
184
185
185
189
197
197
197
197
197
197
197
197
197
197
197
197
201
Basic Weighted Avg Shares
2,894
3,332
3,374
3,054
3,296
3,321
3,674
3,849
3,573
3,937
4,305
4,604
5,851
6,240
6,789
7,023
7,080
Sales/Revenue/Turnover
11.17
6.23
6.53
8.68
11.45
11.55
11.38
14.07
11.16
12.95
16.26
19.06
19.42
20.04
20.74
19.37
20.51
Operating Margin (%)
119
147
137
141
153
165
192
193
198
229
234
221
299
348
405
434
440
Depreciation Expense
210
247
276
298
374
348
340
363
374
376
524
707
815
835
881
928
1,027
Net Income, GAAP
22.56
21
14.44
17.23
16.32
20.66
19.48
21.24
17.3
19.7
19.07
17.45
17.59
19.47
20.47
17.07
18.13
Effective Tax Rate (%)
7.26
7.41
8.18
9.77
11.36
10.47
9.26
9.44
10.48
9.56
12.17
15.35
13.94
13.38
12.97
13.21
14.51
Profit Margin (%)
1,426
1,313
1,403
1,495
1,398
1,426
1,311
1,517
1,611
1,801
1,951
3,068
2,710
3,047
3,341
3,304
3,128
Working Capital
223
30
40
127
181
213
47
187
152
144
202
290
419
445
368
204
200
LT Debt
2,914
2,960
3,155
3,582
3,606
3,887
4,197
4,202
4,246
4,646
4,906
6,800
7,436
8,137
8,976
9,287
9,324
Total Equity
7.13
4.25
4.73
5.21
7.34
6.76
6.89
8.11
5.84
7.19
9.54
9.68
9.78
10.15
11.01
10.95
11.76
Return on Invested Capital (%)
4.23
6.61
7.31
7.19
8.7
7.46
6.45
5.74
6.07
5.11
7.24
7.93
5.34
5.45
4.85
5.97
6.86
Return on Capital (%)
7.81
9.07
9.86
9.71
11.35
10.16
9.37
9.83
10.18
10.11
13.56
17.01
17.93
16.61
15.72
15.42
17.3
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
925
918
837
LT Borrowings
5
- -
- -
LT Finance Leases
199
202
200
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
197
197
197
Market Capitalization
10,525
11,329
11,311

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5,461
5,483
5,775
Cash, Cash Equivalents & STI
2,385
2,383
2,322
Accounts Receivable, Net
1,085
1,082
1,250
Inventories
1,569
1,598
1,697
Total Current Liabilities
2,157
2,681
2,647
Payables & Accruals
- -
- -
- -
ST Debt
925
918
837
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.53%
14.23%
3.46%
Free Cash Flow
236.96%
444.12%
15.35%
Net Income, GAAP
11.08%
12.68%
5.36%
Sales/Revenue/Turnover
8.07%
10.58%
3.44%
Total Cash Common Dividend
- -
- -
3.7%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,614
1,760
1,742
1,673
6,789
2025
1,640
1,828
1,770
1,785
7,023
2026
1,652
1,873
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.29
1.1
1.11
0.99
4.48
2025
0.99
0.91
1.56
1.17
4.72
2026
1.18
1.2
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.45
2025
- -
- -
- -
- -
2.55
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Standard Chem. & Pharm. Co., Ltd. is a pharmaceutical company based in Tainan City, Taiwan, founded in 1967. The company specializes in the research, development, manufacture, and sale of pharmaceutical products, dietary supplements, and active pharmaceutical ingredients (APIs). Its product portfolio includes finished dosage forms for therapeutic areas such as metabolic, respiratory, musculoskeletal, digestive, circulatory, cardiovascular, nervous systems, anti-infectives, urogenital system, sex hormones, and topical dermatology. The company also produces western medicines, nutritional and functional foods, biochemical nutrition products, and preventive medicines. In addition, Standard Chem. & Pharm. offers medical equipment, animal medicines, cosmetics, and milk powder. It operates as a Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO), focusing on innovative drug delivery systems including osmotic-controlled release, micro-encapsulation, pulsatile controlled-release, and lyophilization. Its manufacturing facilities hold approvals from health authorities in the United States, Japan, and Southeast Asian countries. Recent strategic developments include collaboration with major Japanese pharmaceutical companies to expand market presence, and forming strategic alliances with API manufacturers. The company continues to emphasize regulatory compliance and quality assurance aligned with international standards while pursuing innovative technology and superior customer service. These initiatives align with the company’s long-standing corporate philosophy centered on professionalism, excellence, social responsibility, and sustainable growth in the global pharmaceutical industry. Standard Chem. & Pharm. primarily serves domestic and international markets, maintaining a strong reputation for high-quality pharmaceutical solutions.